109 related articles for article (PubMed ID: 35924703)
1. [Clinical Investigation of Immune Checkpoint Inhibitor-Associated Kidney Injury in Patients with Urologic Cancers].
Kozen N; Tanaka T; Shindo T; Hashimoto K; Kobayashi K; Masumori N
Hinyokika Kiyo; 2022 Jul; 68(7):211-215. PubMed ID: 35924703
[TBL] [Abstract][Full Text] [Related]
2. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use.
Min JW; Lim JU
Semin Oncol; 2022 Apr; 49(2):141-147. PubMed ID: 35264308
[TBL] [Abstract][Full Text] [Related]
5. [Side effects of immune checkpoint inhibitor treatment of urological tumors].
Grimm MO; Gottschlich T; Ali N; Foller S; Leucht K
Urologe A; 2021 Jun; 60(6):803-815. PubMed ID: 34100956
[TBL] [Abstract][Full Text] [Related]
6. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
[TBL] [Abstract][Full Text] [Related]
7. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
8. High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors--A nationwide register-based cohort study.
Sørup S; Darvalics B; Russo L; Oksen D; Lamy FX; Verpillat P; Aa K; Ht S; Cronin-Fenton D
Cancer Med; 2021 Jul; 10(14):4957-4963. PubMed ID: 34105315
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Seethapathy H; Street S; Strohbehn I; Lee M; Zhao SH; Rusibamayila N; Chute DF; Gao X; Michaelson MD; Rahma OE; Choueiri TK; McGregor B; Sonpavde G; Salabao C; Kaymakcalan MD; Wei X; Gupta S; Motwani S; Leaf DE; Reynolds KL; Sise ME
Eur J Cancer; 2021 Nov; 157():50-58. PubMed ID: 34482189
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
11. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
12. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates.
Singh S; Clemente LC; Parra ER; Tchakarov A; Yang C; Li Y; Long JP; Yee C; Lin JS
Oncoimmunology; 2022; 11(1):2124678. PubMed ID: 36185804
[TBL] [Abstract][Full Text] [Related]
13. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
Tzeng A; Tzeng TH; Ornstein MC
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599022
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature.
Bimbatti D; Maruzzo M; Pierantoni F; Diminutto A; Dionese M; Deppieri FM; Lai E; Zagonel V; Basso U
Crit Rev Oncol Hematol; 2022 Feb; 170():103579. PubMed ID: 35007699
[TBL] [Abstract][Full Text] [Related]
15. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
Mori K; Quhal F; Yanagisawa T; Katayama S; Pradere B; Laukhtina E; Rajwa P; Mostafaei H; Sari Motlagh R; Kimura T; Egawa S; Bensalah K; Karakiewicz PI; Schmidinger M; Shariat SF
Int Immunopharmacol; 2022 Jul; 108():108720. PubMed ID: 35339843
[TBL] [Abstract][Full Text] [Related]
16. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease.
Bekku K; Nagasaki N; Tsuboi I; Takamoto A; Katayama S; Araki M
Int J Urol; 2023 Oct; 30(10):931-933. PubMed ID: 37278602
[No Abstract] [Full Text] [Related]
18. Editorial Comment on "Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease".
Kandori S
Int J Urol; 2023 Oct; 30(10):933. PubMed ID: 37431801
[No Abstract] [Full Text] [Related]
19. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
20. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
